|
|
47865 Fremont Blvd.
Fremont, CA 94538 USA
phone:510-933-7600
fax:510.933.7659
|
|
| Symbol |
Private |
| Founded |
2003 |
| Employees |
25 |
|
|
| www.neovistainc.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Age-Related Macular Degeneration (ARMD) Treatment Using Targeted Strontium-90 Radiation. |
|
| Management |
| John N. Hendrick, President & CEO; Tony Moses, Vice President of Marketing & Sales; Tim Dumke, Vice President of Finance; David Gyorke, Vice President of R&D & Operations; Anil Patel, Director of Regulatory Affairs & Quality Assurance |
| |
|
|
| |
|
| Keywords |
| age-related macular degeneration, ophthalmology, retina |
|
|
|
| Description |
|
NeoVista develops and markets technology designed to treat wet age-related macular degeneration using targeted strontium-90 beta radiation. This isotope is delivered through a single minimally-invasive surgical procedure lasting approximately 45 minutes in length and producing therapeutic benefits enduring for at least 36 months. |
|
|
| Status |
| Phase III trials are expected to conclude in 2011, following, which, the company anticipates FDA approval. (It has already received CE Mark approval.) The company closed an $18 million Series D Preferred Venture financing round in March 2009. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members